ASPG encodes asparaginase, a multifunctional enzyme with diverse catalytic activities including asparaginase, lysophospholipase, and PAF acetylhydrolase functions 1. The enzyme exhibits lysophospholipase activity towards lysophosphatidylinositol (LPI), playing a critical role in lipid metabolism and insulin signaling 2. ASPG's asparaginase activity, dependent on a critical threonine residue at position 19, enables it to deprive cancer cells of asparagine, leading to cytotoxic effects specifically in leukemic cell lines while sparing normal cells 1. In hepatic tissue, ASPG negatively correlates with insulin sensitivity, where its lysophospholipase activity catabolizes LPI, leading to suppression of tyrosine phosphatase PTP1B and modulation of insulin resistance 2. The enzyme shows significant therapeutic potential in cancer treatment, particularly for acute lymphoblastic leukemia, where engineered ASPG-overexpressing CAR-T cells demonstrate enhanced antitumor immunity through metabolic reprogramming and induction of central memory T cell phenotypes 3. ASPG has been identified as a prognostic biomarker in colorectal cancer, where it is part of inflammatory gene signatures associated with patient outcomes 4 and amino acid metabolism-related prognostic models 5.